Pressemeddelelse

Cinclus Pharma to present linaprazan glurate data at the European Gastroenterology Week (UEGW)

Cinclus Pharma Holding AB (publ), a late-stage clinical pharmaceutical company developing the next-generation treatments for acid-related diseases, today announced that the company will present an abstract on linaprazan glurate at the upcoming United European Gastroenterology Week (UEGW) in Berlin. The abstract highlights positive data on the optimized tablet formulation developed for Phase III studies and future commercialization.

The abstract titled Optimised biopharmaceutical and pharmaconkinetic properties of a linaprazan glurate tablet formulation to be used in Phase III, will be presented by Dr. Kajsa Larsson, Chief Medical Officer at Cinclus Pharma. The data demonstrate that the optimized linaprazan glurate HCl tablet formulation achieves approximately a two-fold increase in bioavailability compared with the formulation used in earlier studies, with only a minor impact observed when administered under fasting versus fed conditions.

European Gastroenterology Week (UEGW), UEG Week is a 4-day annual congress, bringing together digestive health experts from around the world to share the latest multidisciplinary research and advancements. UEG Week 2025 will take place in Berlin and online on October 4-7.

“It is gratifying to be able to present positive data on the good pharmacokinetic properties of the new linaprazan glurate formulation at one of the world's leading gastroenterology conferences. The presented results are encouraging for our first Phase III study, HEEALING 1, that now has been initiated.”, said Kajsa Larsson, Chief Medical Officer at Cinclus Pharma.

The abstract is available on UEGW’s website: https://programme.ueg.eu/2025/#/week/details/presentations/2526

About Cinclus Pharma

Cinclus Pharma Holding AB (publ) is a late-stage clinical pharmaceutical company developing drugs for the treatment of acid-related diseases and disorders of the upper gastrointestinal tract. The company's leading drug candidate is linaprazan glurate, a prodrug of P-CAB linaprazan, which was originally developed by AstraZeneca. Linaprazan glurate has the potential to heal erosions in the esophageal mucosa and relieve symptoms of gastroesophageal reflux disease (GERD) more effectively than current treatments like proton pump inhibitors (PPI). The safety and efficacy of linaprazan and linaprazan glurate have been documented in over 30 phase I and two phase II studies involving more than 3,000 participants. The first Phase III study commenced in 2025. GERD affects approximately 133 million adults in the US and EU, and there is a significant need for new drugs to treat the most severe cases: around 10 million patients. Linaprazan glurate is developed to meet these needs. For more information, visit www.cincluspharma.com.